Literature DB >> 2666576

Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

P Jenner1.   

Abstract

The primary pathological change in Parkinson's disease is the destruction of dopamine containing cells in the zona compacta of substantia nigra. The cause of nigral cell death and the underlying mechanism remains elusive. However, the discovery of the selective nigral neurotoxin MPTP and its ability to inhibit mitochondrial energy metabolism via its metabolite MPP+ and to generate superoxide radicals suggests processes by which nigral cell death might occur. Recent postmortem evidence in brain tissue from patients dying with Parkinson's disease also suggests the occurrence of some on-going toxic mechanism. This may be a free radical process stimulated by an excess of iron within substantia nigra coupled to a generalised decrease in brain ferritin content. These data suggest altered iron handling occurs in Parkinson's disease which may lead to the generation of toxic oxygen species such as superoxide radicals. There is also evidence for an inhibition of mitochondrial function in the substantia nigra in patients with Parkinson's disease. So there may be a close association between the actions of the synthetic neurotoxin MPTP and the underlying cause of idiopathic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2666576      PMCID: PMC1033306          DOI: 10.1136/jnnp.52.suppl.22

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  56 in total

1.  The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.

Authors:  M Nomoto; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1988-11-11       Impact factor: 3.046

2.  Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.

Authors:  P Jenner; H Taquet; A Mauborgne; J T Benoliel; F Cesselin; S Rose; F Javoy-Agid; Y Agid; C D Marsden
Journal:  J Neurochem       Date:  1986-11       Impact factor: 5.372

3.  Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine.

Authors:  W J Nicklas; I Vyas; R E Heikkila
Journal:  Life Sci       Date:  1985-07-01       Impact factor: 5.037

4.  The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment.

Authors:  A J Bradbury; B Costall; P G Jenner; M E Kelly; C D Marsden; R J Naylor
Journal:  Neurosci Lett       Date:  1985-07-31       Impact factor: 3.046

5.  The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.

Authors:  M Nomoto; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1985-06-04       Impact factor: 3.046

6.  1-Methyl-4-phenylpyridine (MPP+) is toxic to mesencephalic dopamine neurons in culture.

Authors:  C Mytilineou; G Cohen; R E Heikkila
Journal:  Neurosci Lett       Date:  1985-06-04       Impact factor: 3.046

7.  Studies on the 1-methyl-4-phenyl-2,3-dihydropyridinium species 2,3-MPDP+, the monoamine oxidase catalyzed oxidation product of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  L A Peterson; P S Caldera; A Trevor; K Chiba; N Castagnoli
Journal:  J Med Chem       Date:  1985-10       Impact factor: 7.446

8.  Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.

Authors:  P A Ballard; J W Tetrud; J W Langston
Journal:  Neurology       Date:  1985-07       Impact factor: 9.910

9.  Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B.

Authors:  R E Heikkila; L Manzino; F S Cabbat; R C Duvoisin
Journal:  J Neurochem       Date:  1985-10       Impact factor: 5.372

10.  Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin.

Authors:  R J D'Amato; D F Benham; S H Snyder
Journal:  J Neurochem       Date:  1987-02       Impact factor: 5.372

View more
  12 in total

Review 1.  Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases.

Authors:  G Brent Irvine; Omar M El-Agnaf; Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Med       Date:  2008 Jul-Aug       Impact factor: 6.354

2.  EGb761 blocks MPP+-induced lipid peroxidation in mouse corpus striatum.

Authors:  P Rojas; B Garduño; C Rojas; R M Vigueras; J Rojas-Castañeda; C Rios; N Serrano-Garcia
Journal:  Neurochem Res       Date:  2001-11       Impact factor: 3.996

3.  The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.

Authors:  A Ueki; L Rosén; B Andbjer; U B Finnman; U Altamimi; A M Janson; M Goldstein; L F Agnati; K Fuxe
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

4.  EGb761 pretreatment reduces monoamine oxidase activity in mouse corpus striatum during 1-methyl-4-phenylpyridinium neurotoxicity.

Authors:  Patricia Rojas; Carolina Rojas; Manuchair Ebadi; Sergio Montes; Antonio Monroy-Noyola; Norma Serrano-García
Journal:  Neurochem Res       Date:  2004-07       Impact factor: 3.996

Review 5.  Toward an understanding of the molecular mechanisms of physiological cell death.

Authors:  D L Vaux
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

Review 6.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

7.  Altered cerebellar connectivity in Parkinson's patients ON and OFF L-DOPA medication.

Authors:  Sara B Festini; Jessica A Bernard; Youngbin Kwak; Scott Peltier; Nicolaas I Bohnen; Martijn L T M Müller; Praveen Dayalu; Rachael D Seidler
Journal:  Front Hum Neurosci       Date:  2015-04-21       Impact factor: 3.169

8.  Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.

Authors:  Ting Yan; Joshua Dominic Rizak; ShangChuan Yang; Hao Li; Baihui Huang; Yuanye Ma; Xintian Hu
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

9.  Oxidative stress and regulation of Pink1 in zebrafish (Danio rerio).

Authors:  Madhusmita Priyadarshini; Lori A Orosco; Pertti J Panula
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

Review 10.  The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light.

Authors:  Joanna F Collingwood; Mark R Davidson
Journal:  Front Pharmacol       Date:  2014-08-19       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.